CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Electronic Brachytherapy for Nonmelanoma Skin Cancer

This policy governs coverage determinations for the use of electronic (high-dose-rate) brachytherapy to treat nonmelanoma skin cancers (basal cell and squamous cell) for members of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyElectronic Brachytherapy for Nonmelanoma Skin Cancer

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2023

Next Review DateN/A

Key ActionDo not submit electronic brachytherapy (e.g., CPT 0394T) for treatment of nonmelanoma skin cancer as it is considered not covered / not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

0394TProcedure code

C44.00–C44.99Diagnosis range

80%–92%5‑yr control (context)

Coverage Criteria — Electronic Brachytherapy for Nonmelanoma Skin Cancer

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered / Not medically necessary

Covered when ALL of the following are met:

Primary policy stance: Electronic brachytherapy for treatment of nonmelanoma skin cancer is considered not covered / not medically necessary because the evidence is insufficient to determine effects on health outcomes.

No randomized controlled trials identified; evidence consists of systematic reviews, a prospective cohort study, and case series with limited confidence.

Electronic brachytherapy for treatment of nonmelanoma skin cancer is excluded from coverage because the available evidence is insufficient to determine its effects on health outcomes. The policy statement specifies that electronic brachytherapy is "considered not covered" due to insufficient evidence to determine effects on health outcomes, and for Commercial Products it is "considered not medically necessary" for the same reason. This rationale reflects the absence of high-confidence comparative data demonstrating clinical benefit over standard treatments.

For Commercial Products, electronic brachytherapy for nonmelanoma skin cancer is explicitly designated not medically necessary because the evidence is insufficient to determine effects on health outcomes. The policy also identifies CPT 0394T (High dose rate electronic brachytherapy, skin surface application, per fraction) as a procedure code that is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products when billed with the ICD-10 diagnosis range C44.00–C44.99.

Provider Actions and Billing Impact

Note

Prior Authorization Not Applicable

Prior authorization is not applicable for electronic brachytherapy; however, this service is not covered / not medically necessary under this policy. Providers should note that a prior authorization request will not change coverage for noncovered services.

Prior Authorization: Not applicable — provider note that PA is not used but service is not covered

Note

Therapy Alternatives

When choosing therapy for nonmelanoma skin cancer (NMSC), standard alternatives include surgical excision (preferred with highest cure rates) and external-beam radiotherapy or other radiotherapy modalities when surgery is not feasible. Consider recurrence risk, preservation of function, patient expectations, and adverse events when selecting treatment.

Standard alternatives: surgical excision, external-beam radiation, cryosurgery, topical therapy

Documentation Required

Benefit Verification and Member Documents

Verify member benefits and coverage before providing services. Benefits may vary by group/contract; refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for benefit determination. Contact the provider call center for member-specific eligibility and benefit questions.

Check Benefit Booklet / Evidence of Coverage / Subscriber Agreement
Contact provider call center for member-specific benefits and eligibility

Denial Risk

Denial Risk for Electronic Brachytherapy

Electronic brachytherapy (including CPT 0394T when billed with ICD-10 codes C44.00–C44.99) is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products. Claims for these services may be denied; review coding and diagnosis if submitted.

Affected code: CPT 0394T — High dose rate electronic brachytherapy, skin surface application, per fraction
Affected diagnosis range: ICD-10 C44.00–C44.99
Denial risk: Claims (including CPT 0394T with ICD-10 C44.00–C44.99) may be denied

Background

Basal cell carcinoma and squamous cell carcinoma (nonmelanoma skin cancers) are common and are most effectively managed with surgical excision when feasible. Radiotherapy — principally external-beam techniques — is an accepted alternative for lesions that are not amenable to surgery or where surgery would cause unacceptable cosmetic or functional outcomes. Electronic brachytherapy is a localized, high-dose-rate technique that uses a miniaturized electronic X-ray source with surface applicators or molds to deliver a focused dose to superficial, well-circumscribed lesions, typically delivered over multiple fractions within a month.

When considering effectiveness in context, published radiotherapy series report 5-year local control rates in the approximate range of 80%–92% for radiotherapy approaches used to treat nonmelanoma skin cancers. The policy notes that evidence for electronic brachytherapy consists primarily of systematic reviews, prospective cohort studies, and case series with limited confidence, and no randomized controlled trials were identified to establish superiority or equivalence to standard external-beam radiotherapy or surgical management.

Definitions

Electronic brachytherapy — definition and key features

DefinitionA form of brachytherapy that uses a miniaturized electronic X-ray source (rather than a radionuclide) with applicators or pliable molds (e.g., silicone or polymethylmethacrylate) fitted to the tumor surface to deliver a focused, uniform radiation dose to superficial, well-circumscribed skin lesions.

Applicators / MoldsPliable molds (silicone or polymethylmethacrylate) are constructed and fitted to the tumor surface to permit treatment of nonflat surfaces (such as the nose or ear).

Radiation sourceUses a miniaturized electronic X-ray source inserted into the mold to deliver a uniform radiation dose directly to the lesion (no radionuclide used).

Treatment courseMultiple treatment sessions are typically delivered within a short period (commonly within a month).

Intended lesionsFeasible for well-circumscribed, superficial tumors due to focused, surface-applied dosing and shielding to spare surrounding healthy tissue and organs.